Albertsons Companies (ACI) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
14 Apr, 2026Executive summary
Q4 identical sales rose 0.7% to $20.3 billion, aided by an extra week, with digital sales up 16% and Adjusted EBITDA reaching $903 million, exceeding expectations.
Net loss of $481 million in Q4 was driven by a $600 million after-tax charge for the opioid settlement; adjusted net income was $252 million.
Full-year identical sales increased 2%, digital sales up 21%, and net income was $217 million; adjusted net income was $1.2 billion.
Over $1.8 billion was returned to shareholders in 2025 via dividends and share repurchases, reflecting disciplined capital allocation.
Strategic focus remains on personalization, digital transformation, and leveraging a strong store network for competitive advantage.
Financial highlights
Q4 Adjusted EBITDA was $903 million, including $68 million from the 53rd week; Adjusted EPS was $0.48 per diluted share.
Full-year identical sales increased 2%, with $3.9 billion in Adjusted EBITDA.
Gross margin in Q4 was 27.2%, down 25 bps year-over-year, mainly due to digital sales mix shift and higher delivery costs.
Q4 interest expense rose to $141 million from $101 million last year, reflecting higher borrowings and an extra week.
Selling and administrative expenses rose to 29.6% of net sales in Q4, up from 25.7% last year, largely due to the opioid settlement charge.
Outlook and guidance
Fiscal 2026 identical sales expected at 0%-1%, or 1.5%-2.5% excluding a 150 bps IRA headwind.
Adjusted EBITDA guidance for 2026 is $3.85-$3.93 billion; Adjusted EPS expected at $2.22-$2.32, including $600 million in share repurchases.
CapEx planned at $2-$2.2 billion, focusing on new stores, remodels, AI, and digital investments.
Sequential improvement in sales and earnings anticipated through 2026, with Q1 being the most pressured quarter.
Latest events from Albertsons Companies
- Q3 delivered solid sales and digital growth, but faces post-merger litigation and margin pressure.ACI
Q3 202410 Jan 2026 - Identical sales and digital growth lifted revenue, but margins narrowed amid ongoing investments.ACI
Q1 20259 Jan 2026 - Q3 2025 saw 2.4% identical sales growth, strong digital gains, and major capital actions.ACI
Q3 20257 Jan 2026 - Q2 2025 saw 2.0% revenue growth, higher net income, and a $750M share buyback announcement.ACI
Q2 20257 Jan 2026 - Q4 delivered strong digital and pharmacy growth, but margin pressure tempers 2025 optimism.ACI
Q4 202419 Dec 2025 - Board recommends against all shareholder proposals; focus remains on digital growth and ESG impact.ACI
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, auditor, and pay, with focus on merger, governance, and ESG.ACI
Proxy Filing1 Dec 2025 - Annual proxy statement outlines voting items and confirms standard shareholder meeting.ACI
Proxy Filing1 Dec 2025 - Definitive additional proxy materials filed for shareholder voting, with no fee required.ACI
Proxy Filing1 Dec 2025